Shionogi (TYO:4507) said Taiwan's Food and Drug Administration accepted the new drug application for ensitrelvir fumaric acid submitted by its Taiwanese subsidiary.
A contract for purchasing ensitrelvir for government stockpiling was also finalized with the Taiwan Centers for Disease Control, according to a Wednesday bourse filing.
Ensitrelvir is an oral antiviral that inhibits SARS-CoV-2 replication, and while it has full approval in Japan and special access in Singapore, it remains investigational elsewhere.
Price (JPY): $2263.00, Change: $+31, Percent Change: +1.39%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。